ABOS RSI Chart
Last 7 days
2.9%
Last 30 days
31.1%
Last 90 days
20.5%
Trailing 12 Months
-8.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 19, 2024 | oconnell daniel joseph | sold | -52,753 | 3.4706 | -15,200 | president and ceo |
Jan 19, 2024 | meisner derek m | sold | -31,048 | 3.4757 | -8,933 | chief legal officer & corp sec |
Jan 18, 2024 | barton russell | sold | -10,555 | 3.7258 | -2,833 | chief operating officer |
Jan 18, 2024 | siemers eric | sold | -11,603 | 3.7144 | -3,124 | chief medical officer |
Jan 18, 2024 | zuga matt | sold | -15,716 | 3.705 | -4,242 | cfo & chief business officer |
Jan 02, 2024 | meisner derek m | acquired | - | - | 91,000 | chief legal officer & corp sec |
Jan 02, 2024 | zuga matt | acquired | - | - | 106,000 | cfo & chief business officer |
Jan 02, 2024 | oconnell daniel joseph | acquired | - | - | 401,000 | president and ceo |
Jan 02, 2024 | siemers eric | acquired | - | - | 94,000 | chief medical officer |
Jan 02, 2024 | barton russell | acquired | - | - | 73,000 | chief operating officer |
Which funds bought or sold ABOS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -0.92 | -640,811 | 7,063,880 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 300 | 643,351 | 881,142 | -% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 91,000 | 91,000 | 0.01% |
Feb 23, 2024 | Chicago Partners Investment Group LLC | added | 34.88 | 14,211 | 59,157 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | added | 3,501 | 2,252,070 | 2,321,740 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 111 | 89,000 | 182,000 | -% |
Feb 14, 2024 | GROUP ONE TRADING, L.P. | new | - | 28,965 | 28,965 | -% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | sold off | -100 | -477,387 | - | -% |
Feb 14, 2024 | Caption Management, LLC | unchanged | - | -12,400 | 153,600 | -% |
Feb 14, 2024 | ExodusPoint Capital Management, LP | new | - | 124,000 | 124,000 | -% |
Unveiling Acumen Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Acumen Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Acumen Pharmaceuticals, Inc. News
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | 8.3% | 310 | 286 | 177 | 188 | 197 | 203 | 212 | 220 | 230 | 235 | 73.00 | 44.00 |
Current Assets | 12.8% | 247 | 219 | 150 | 144 | 180 | 203 | 191 | 192 | 199 | 205 | 71.00 | 44.00 |
Cash Equivalents | -29.3% | 67.00 | 95.00 | 77.00 | 78.00 | 130 | 158 | 111 | 109 | 122 | 136 | 69.00 | 44.00 |
Net PPE | -100.0% | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
Liabilities | 607.6% | 43.00 | 6.00 | 9.00 | 9.00 | 8.00 | 7.00 | 5.00 | 4.00 | 5.00 | 1.00 | 5.00 | 6.00 |
Current Liabilities | 112.7% | 13.00 | 6.00 | 9.00 | 9.00 | 8.00 | 7.00 | 5.00 | 4.00 | 5.00 | - | - | - |
Shareholder's Equity | -4.7% | 267 | 280 | 169 | 179 | 189 | 197 | 207 | 216 | 225 | 233 | - | - |
Retained Earnings | -8.0% | -222 | -206 | -193 | -181 | -170 | -157 | -146 | -136 | -127 | -119 | -115 | -26.96 |
Additional Paid-In Capital | 0.5% | 489 | 487 | 363 | 361 | 360 | 355 | 354 | 354 | 353 | 353 | 9.00 | 8.00 |
Shares Outstanding | 0% | 58.00 | 58.00 | 41.00 | 41.00 | 41.00 | 40.00 | 40.00 | 40.00 | 40.00 | 13.00 | - | 0.00 |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | 35.6% | -8,314 | -12,905 | -11,670 | -10,175 | -11,203 | -9,183 | -6,468 | -8,299 | -3,639 | -7,688 | -4,264 | -2,370 | - | - | - |
Share Based Compensation | 2.1% | 1,634 | 1,600 | 1,521 | 1,390 | 888 | 840 | 715 | 618 | 365 | 304 | 127 | 126 | - | - | - |
Cashflow From Investing | 46.9% | -48,807 | -92,001 | 11,064 | -41,927 | -20,420 | 55,919 | 8,785 | -5,099 | - | - | - | - | - | - | - |
Cashflow From Financing | -76.3% | 29,134 | 122,764 | - | - | 4,184 | -263 | - | - | 10.00 | 168,781 | - | - | - | - | - |
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses | ||
Research and development | $ 42,318 | $ 32,361 |
General and administrative | 18,820 | 12,876 |
Total operating expenses | 61,138 | 45,237 |
Loss from operations | (61,138) | (45,237) |
Other income (expense) | ||
Interest income | 10,791 | 2,392 |
Change in fair value of embedded derivatives | (1,360) | 0 |
Interest expense | (581) | 0 |
Other expense, net | (83) | (11) |
Total other income | 8,767 | 2,381 |
Net loss | (52,371) | (42,856) |
Other comprehensive gain (loss) | ||
Unrealized gain (loss) on marketable securities | 1,063 | (520) |
Comprehensive loss | $ (51,308) | $ (43,376) |
Net loss per common share, basic (in dollars per share) | $ (1.08) | $ (1.06) |
Net loss per common share, diluted (in dollars per share) | $ (1.08) | $ (1.06) |
Weighted-average shares outstanding, basic (in shares) | 48,609,383 | 40,601,936 |
Weighted-average shares outstanding diluted (in shares) | 48,609,383 | 40,601,936 |
BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 66,886 | $ 130,101 |
Marketable securities, short-term | 176,636 | 47,504 |
Prepaid expenses and other current assets | 3,093 | 2,724 |
Total current assets | 246,615 | 180,329 |
Marketable securities, long-term | 62,553 | 15,837 |
Restricted cash | 233 | 0 |
Property and equipment, net | 122 | 165 |
Right-of-use asset | 381 | 105 |
Other assets | 221 | 151 |
Total assets | 310,125 | 196,587 |
Current liabilities | ||
Accounts payable | 1,379 | 1,640 |
Accrued clinical trial expenses | 4,387 | 2,717 |
Accrued expenses and other current liabilities | 6,339 | 3,350 |
Finance lease liability, short-term | 756 | 0 |
Operating lease liability, short-term | 110 | 105 |
Total current liabilities | 12,971 | 7,812 |
Operating lease liability, long-term | 284 | 0 |
Debt, long-term | 29,897 | 0 |
Total liabilities | 43,152 | 7,812 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2023 and 2022; 57,910,461 and 41,025,062 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 6 | 4 |
Additional paid-in capital | 489,453 | 359,949 |
Accumulated deficit | (222,798) | (170,427) |
Accumulated other comprehensive income (loss) | 312 | (751) |
Total stockholders’ equity | 266,973 | 188,775 |
Total liabilities and stockholders’ equity | $ 310,125 | $ 196,587 |